Comparative Pharmacology
Head-to-head clinical analysis: NOVOLOG FLEXPEN versus NOVOLOG MIX 70 30 PENFILL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NOVOLOG FLEXPEN versus NOVOLOG MIX 70 30 PENFILL.
NOVOLOG FLEXPEN vs NOVOLOG MIX 70/30 PENFILL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Insulin analog that lowers blood glucose by binding to insulin receptors, facilitating cellular uptake of glucose, and inhibiting hepatic glucose production.
Novolog Mix 70/30 is a biphasic insulin analog suspension containing 70% insulin aspart protamine (intermediate-acting) and 30% insulin aspart (rapid-acting). Insulin aspart binds to the insulin receptor (IR) on target cells (muscle, adipose, liver), activating tyrosine kinase signaling, which promotes glucose uptake via GLUT4 translocation, inhibits hepatic gluconeogenesis, and stimulates glycogen synthesis and lipogenesis.
Subcutaneous injection; 0.5 to 1.0 unit/kg/day divided into doses at mealtimes; dose individualization based on metabolic needs and blood glucose monitoring.
Subcutaneous injection, typically 0.5–1 unit/kg/day divided into two doses: two-thirds in the morning and one-third in the evening, adjusted based on blood glucose levels.
None Documented
None Documented
Terminal elimination half-life: 5-7 minutes (free insulin aspart in plasma); clinically, the prolonged action (up to 6 hours) reflects continued absorption from subcutaneous depot, not elimination half-life
Biphasic: first phase (distribution) 0.5-1 h; terminal (elimination) 5-7 h (insulin aspart component). Clinical context: covers prandial and basal needs with twice-daily dosing.
Primarily renal (60-80% as unchanged drug via glomerular filtration and tubular reabsorption); biliary/fecal excretion minimal (<2%)
Renal: 100% (protamine and insulin are metabolized and excreted via kidneys; no unchanged drug excreted in urine). Biliary/fecal: negligible.
Category C
Category C
Insulin Analog
Insulin Analog